OCE 2.0? US FDA Leadership Change May Present Opportunity To Grant Full Review Authority

With a new commissioner expected next year, a restructuring may allow the Oncology Center of Excellence to assume sign-off authority for biologics and devices along with drugs.

vintage movie poster number 2. (photo illustration/Alamy image)
OCE could be counting down to a new, more authoritative structure. • Source: Photo illustration/Alamy image

Leadership changes at the US Food & Drug Administration put the agency at a key “inflection point” for the next phase of the implementation of the Oncology Center of Excellence – and may present an opportunity for the center to assume sign-off authority for biologics and devices along with drugs.

When it was stood up five years ago, the initial structure had OCE collaborating across centers within a framework that...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet